Serum uric acid (SUA) is associated with microvascular disease that could alter coronary blood flow and prognosis. We evaluated the effects of admission SUA levels on coronary blood flow and prognosis in 185 consecutive patients with ST-segment elevation myocardial infarction (STEMI) who underwent acute primary percutaneous coronary intervention (PCI).
Methods
Patients undergoing PCI for an acute STEMI were stratified into elevated SUA (>6.5 mg/dL) and normal SUA group (≤6.5 mg/dL). Primary end points were post-PCI myocardial blood flow and in-hospital and 1-year mortality.
Results
Serum uric acid level was high in 45 patients (24%) on admission. Subjects with elevated SUA had a higher prevalence of hypertension, previous myocardial infarction, multivessel disease, and Killip functional class III or higher. Corrected thrombolysis in myocardial infarction (TIMI) frame count was longer, and mean TIMI myocardial perfusion grade was higher in patients with elevated uric acid compared with controls. Patients with elevated SUA levels had higher in-hospital (6.6% vs 2.8%, P < 0.01) and 1-year mortality (11.1% vs 5.7%, P < 0.01). Major adverse cardiac events were higher in patients with elevated SUA levels both in-hospital (11.1% vs 5.7%, P < 0.01) and at 1 year (17.7% vs 10%, P < 0.05). An elevated admission SUA level also independently predicted both 1-year mortality (odds ratio, 1.41; 95% confidence interval, 1.24-2.69) and abnormal myocardial perfusion detected by TIMI myocardial perfusion grade in STEMI patients undergoing primary PCI (odds ratio, 2.14; 95% confidence interval, 1.17-4.19, respectively).
Conclusions
Elevated SUA level on admission independently predicts impaired myocardial flow and poor prognosis in STEMI patients undergoing primary PCI.
JohnsonRJ, KangDH, FeigD, . Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?Hypertension. 2003;41(6):1183–1190.
2.
AmesBN, CathcartR, SchwiersE, . Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858–6862.
3.
NietoFJ, IribarrenC, GrossMD, . Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?Atherosclerosis. 2000;148(1):131–139.
4.
ReyesAJ, LearyWP. The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid?Cardiovasc Drugs Ther. 2002;16(6):485–487.
5.
LeyvaF, AnkerS, SwanJW, . Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858–865.
6.
BerryCE, HareJM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555(Pt 3):589–606.
7.
GeorgeJ, CarrE, DaviesJ, . High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508–2516.
8.
DoehnerW, AnkerSD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?Heart. 2005;91(6):707–709.
9.
KangDH, ParkSK, LeeIK, . Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553- 3562.
10.
YuMA, Sanchez-LozadaLG, JohnsonRJ, . Uric acid: an inducer of oxidative stress and renin angiotensin system in human vascular endothelial cells. J Hypertension.In press.
11.
KanellisJ, WatanabeS, LiJH, . Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287–1293.
12.
KangDH, NakagawaT, FengL, . A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–2897.
13.
ChengTH, LinJW, ChaoHH, . Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol. 2010;139:42–49.
14.
KanbayM, OzkaraA, SelcokiY, . Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–1233.
15.
SiuYP, LeungKT, TongMK, . Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51–59.
16.
FeigDI, SoletskyB, JohnsonRJ. Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension. JAMA. 2008;300(8):922–930.
17.
OginoK, KatoM, FuruseY, . Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3(1):73–81.
18.
MuirSW, HarrowC, DawsonJ, . Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2008;39(12):3303–3307.
MazzaliM, KanellisJ, HanL, . Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol. 2002;282(6):F991–F997.
21.
Sanchez-LozadaLG, SotoV, TapiaE, . Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol. 2008;295(4):F1134–F1141.
22.
CorryDB, EslamiP, YamamotoK, . Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–275.
23.
Sanchez-LozadaLG, TapiaE, SantamariaJ, . Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):237–247.
24.
SchretlenDJ, InscoreAB, VannorsdallTD, . Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69(14):1418–1423.
KingSB3rd, SmithSCJr, HirshfeldJWJr, . 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51(2):172–209.
27.
GibsonCM, CannonCP, MurphySA, . Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101(2):125–130.
28.
ItoH, MaruyamaA, IwakuraK, . Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93(2):223–228.
29.
IlicetoS, GaliutoL, MarcheseA, . Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J. 1997;18(4):618–624.
30.
MorishimaI, SoneT, MokunoS, . Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995;130(2):239–243.
31.
MorishimaI, SoneT, OkumuraK, . Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36(4):1202–1209.
32.
Van de WerfF, ArdissinoD, BetriuA, . Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003;24:28–66.
33.
AndersonJL, KaragounisLA, BeckerLC, . TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation. 1993;87(6):1829–1839.
34.
GibsonCM, CannonCP, DaleyWL, . TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879–888.
35.
GibsonCM, MurphySA, RizzoMJ, . Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation. 1999;99(15):1945–1950.
36.
SchroderR, DissmannR, BruggemannT, . Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24(2):384–391.
37.
GibsonCM, KarhaJ, MurphySA, . Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. J Am Coll Cardiol. 2003;42(1):7–16.
38.
CutlipDE, WindeckerS, MehranR, . Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–2351.
39.
BrodovY, ChouraquiP, GoldenbergI, . Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology. 2009;114(4):300–305.
40.
DunkelgrunM, WeltenGM, GoeiD, . Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery. Am J Cardiol. 2008;102(7):797–801.
41.
HiyamutaK, ToshimaH, KogaY, . Relationship between coronary risk factor and arteriographic feature of coronary atherosclerosis. Jpn Circ J. 1990;54(4):442–447.
42.
BickelC, RupprechtHJ, BlankenbergS, . Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89(1):12–17.
43.
MadsenTE, MuhlesteinJB, CarlquistJF, . Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol. 2005;25(1):45–49.
44.
TuttleKR, ShortRA, JohnsonRJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001;87(12):1411–1414.
45.
BosMJ, KoudstaalPJ, HofmanA, . Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503–1507.
46.
BrandFN, McGeeDL, KannelWB, . Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985;121(1):11–18.
47.
FreedmanDS, WilliamsonDF, GunterEW, . Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995;141(7):637–644.
48.
LieseAD, HenseHW, LowelH, . Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology. 1999;10(4):391–397.
49.
LazzeriC, ValenteS, ChiostriM, . Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol. 2010;138(2):206–209.
50.
KojimaS, SakamotoT, IshiharaM, . Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol. 2005;96(4):489–495.
51.
ItoH, TomookaT, SakaiN, . Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85(5):1699–1705.
52.
SuenariK, ShiodeN, ShirotaK, . Predictors and long-term prognostic implications of angiographic slow/no-flow during percutaneous coronary intervention for acute myocardial infarction. Intern Med. 2008;47(10):899–906.
53.
HalkinA, SinghM, NikolskyE, . Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005;45(9):1397–1405.
54.
Sanchez-LozadaLG, TapiaE, Lopez-MolinaR, . Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol. 2007;292(4):F1238-F1244.
55.
GibsonCM, MurphySA, KirtaneAJ, . Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44(5):980–987.
56.
MaXL, TsaoPS, ViehmanGE, . Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery. Circ Res. 1991;69(1):95–106.
57.
ManyA, HubelCA, RobertsJM. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol. 1996;174(1 Pt 1):288–291.
58.
MercuroG, VitaleC, CerquetaniE, . Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94(7):932–935.
59.
RuggieroC, CherubiniA, BleA, . Uric acid and inflammatory markers. Eur Heart J. 2006;27(10):1174–1181.
